In April 2022, NHS England and NHS Improvement (NHSEI) announced that the timelines for the evaluation of applications to update the National Genomic Test Directory in 2022/23 are currently under review. Previously, NHSEI planned to publish and implement the 2022/23 Test Directory by April 2022. While the timelines are not confirmed, applications can still be submitted.

On April 25, 2022, the Decision Forum for "New Method" did not prioritize any surgical procedure in the treatment of morbid obesity. Available evidence in the complete method assessment shows minor or no difference in weight loss, diabetes control, or health-related quality of life when using various surgical procedures. The comparative effect on the risk of early mortality, progression of obesity, and obesity-related comorbidities was not possible to determine. The cost differences are non-significant. Further research was recommended.

On April 19, 2022, the Innovation Committee at the Federal Joint Committee (G-BA) has informed of the favorable results of the scientific evaluation of the G-BA Innovation Fund performed by the economic research center Prognos AG.

On April 21, 2022, NHS England and NHS Improvement updated the 2021/22 National Genomic Test Directory (version 3), which lists genomic tests commissioned by NHS England via Genomic Laboratory Hubs. Forty-two new codes (test-indication combinations) were introduced in the cancer field, and fourteen for rare and inherited diseases.

The French National Authority for Health (HAS) released new recommendations about add-on reimbursement of medical devices and medical aids from the meetings of the National Commission for Evaluation of Medical Devices and Health Technologies (CNEDiMTS) in April 2022. Thirty recommendations were published in relation to the registration, modification of registration conditions, and renewal of registration for devices in the List of reimbursable products and services (LPPR). Opinions concern cardiovascular and peripheral vascular, orthopedic, neurovascular, and neuromodulation and other devices, as well as medical aids.

In April 2022, the Clinical Coding and Schedule Development (CCSD) working group, which develops and maintains procedural and diagnostics nomenclatures for private payers in England, published Bulletins 0183 and 0080 with changes to be implemented no later than June 14, 2022. Eleven new procedure codes and nine new diagnostic codes were introduced.

MoveUP is the first digital health app that has reached the level 3 level on the Mhealth validation pyramid. This means that the app is now reimbursed in Belgium.

On April 4, 2022, the Innovation Committee at the Federal Joint Committee (G-BA) published the decisions, which recommended the transfer to standard care for two completed projects. The projects relate to the management of rare diseases and the strengthening of the regional healthcare structures and processes.

A new test called Genedrive System to detect babies at risk of gentamycin-related deafness was developed at the University of Manchester, funded by the National Institute for Health and Care Research (NIHR). On April 02, 2022, NHS England and NHS Improvement announced that Genedrive is now fully CE certified to be used in a clinical setting. The test is expected to be implemented in routine care in all NHS Manchester Foundation Trust hospitals within several weeks.

On April 1, 2022, the entity managing the DRG system in Switzerland, SwissDRG, announced that they will be accepting applications for changes in the DRG system from June 6, 2022, until July 17, 2022. The results of the DRG applications made in 2022 will be reflected in the 2024 version of SwissDRG.

In Q1 of 2022, Health Technology Wales (HTW) published one MedTech-related guidance on transcranial magnetic stimulation in depression treatment. A total of eleven Topic Exploration Reports (TERs) were released in Q1. Based on the TERs conclusions, HTW's Assessment Group decided to proceed with developing an Evidence Appraisal Report (EAR) and Guidance on one topic only - radiofrequency renal denervation for the treatment of resistant hypertension.